Traders Buy High Volume of ACADIA Pharmaceuticals Put Options (ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) saw unusually large options trading on Thursday. Traders acquired 4,776 put options on the stock, AR Network reports. This represents an increase of approximately 116% compared to the average daily volume of 2,209 put options.
In other ACADIA Pharmaceuticals news, CFO Thomas H. Aasen sold 30,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $27.87, for a total value of $836,100.00. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on ACAD shares. Analysts at Ned Davis Research initiated coverage on shares of ACADIA Pharmaceuticals in a research note to investors on Monday. They set a “neutral” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $23.43.
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 15.96% on Thursday, hitting $23.03. 7,752,644 shares of the company’s stock traded hands. ACADIA Pharmaceuticals has a 52-week low of $1.80 and a 52-week high of $29.73. The stock’s 50-day moving average is $23.44 and its 200-day moving average is $17.53. The company’s market cap is $2.045 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.11) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts predict that ACADIA Pharmaceuticals will post $-0.44 earnings per share for the current fiscal year.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.